DOSE ESCALATION FOR INFUSION BIOLOGICS WITH FLEXIBLE DOSING SCHEDULES
Author(s)
Kozma C1, Paris A2, Ingham M3
1CK Consulting, Saint Helena Island, SC, USA, 2Vigilytics, Victor, NY, USA, 3Janssen Scientific Affairs, LLC, Horsham, PA, USA
OBJECTIVES: To describe the frequency of and time to dose escalation for incident infliximab(IFX) or tociluzumab(TCZ) patients. METHODS: This retrospective, observational analysis used national data from Symphony Health Solutions (SHS). All claims for adult IFX or TCZ (index biologic) patients were extracted from January 1, 2009 to December 31, 2011. Proxy eligibility criteria ensured complete claims and excluded pre-index biologic users. IFX and TCZ patients were excluded if their calculated daily dose was <200mg or >1200mg (IFX) and <200mg or >800mg (TCZ) or if the times between infusions were <14 days or <25 days respectively, or if patients had biologic claims in both the prescription and procedure (Px) files. Within the first 180 days post index, patients with ≥3 Px claims were classified by their dose change over the first 3 dosages, reporting any dose increase, dose doubling at any time, the time to dose doubling and the time between claims (infusions). Results are descriptive, and cohorts were not adjusted for differences. RESULTS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PIH51
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
Multiple Diseases, Reproductive and Sexual Health